Publications
PreMeta: Facilitates the Exchange of Information Between Software Packages for Meta-Analysis (C++)., 2017.
logi: Logistic regression using forward selection (R).. 2.0 ed., 2013.
Haplo.CasGLM: Haplotype specific simultaneous factor selection and collapsing levels in GLM (R).. 3rd ed., 2013.
cSFM: Covariate-adjusted skewed functional model (R).. 1.1 ed., 2014.
CRM2DIM: Dual-Agent Bayesian Continual Reassessment Method (SAS). 1.0 ed., 2019.
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"Weighted NPMLE for the Subdistribution of a Competing Risk." J Am Stat Assoc 114, no. 525 (2019): 259-270.
"Variable Selection for Nonparametric Quantile Regression via Smoothing Spline AN OVA." Stat 2, no. 1 (2013): 255-268.
"Use of historical control data for assessing treatment effects in clinical trials." Pharm Stat 13, no. 1 (2014): 41-54.
"The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies." J Biopharm Stat 25, no. 1 (2015): 66-88.
"UNC-Utah NA-MIC framework for DTI fiber tract analysis." Front Neuroinform 7 (2014): 51.
"UNC-Utah NA-MIC framework for DTI fiber tract analysis." Front Neuroinform 7 (2014): 51.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
"Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases." J Clin Oncol 34, no. 9 (2016): 945-52.
"Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer." J Thorac Oncol 14, no. 2 (2019): 298-303.
"Tests of trend between disease outcomes and ordinal covariates discretized from underlying continuous variables: simulation studies and applications to NHANES 2007-2008." BMC Med Res Methodol 19, no. 1 (2019): 2.
"A Tailored Multivariate Mixture Model for Detecting Proteins of Concordant Change Among Virulent Strains of ." J Am Stat Assoc 113, no. 522 (2018): 546-559.
"Surface Estimation, Variable Selection, and the Nonparametric Oracle Property." Stat Sin 21, no. 2 (2011): 679-705.
"Sufficient dimension reduction via bayesian mixture modeling." Biometrics 67, no. 3 (2011): 886-95.
"Statistical considerations for analysis of microarray experiments." Clin Transl Sci 4, no. 6 (2011): 466-77.
"Static and Dynamic DNA Loops form AP-1-Bound Activation Hubs during Macrophage Development." Mol Cell 67, no. 6 (2017): 1037-1048.e6.
"Spatial regression with covariate measurement error: A semiparametric approach." Biometrics 72, no. 3 (2016): 678-86.
"A spatial dirichlet process mixture model for clustering population genetics data." Biometrics 67, no. 2 (2011): 381-90.
"SNPpy--database management for SNP data from genome wide association studies." PLoS One 6, no. 10 (2011): e24982.
"Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy." Nat Commun 11, no. 1 (2020): 6410.
"Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy." Nat Commun 11, no. 1 (2020): 6410.
"Risk calculators are useful but..." J Thorac Cardiovasc Surg 151, no. 3 (2016): 706-707.
"Responses to discussants of 'Joint modeling of survival and longitudinal non-survival data: current methods and issues. report of the DIA Bayesian joint modeling working group'." Stat Med 34, no. 14 (2015): 2202-3.
"Responses to discussants of 'Joint modeling of survival and longitudinal non-survival data: current methods and issues. report of the DIA Bayesian joint modeling working group'." Stat Med 34, no. 14 (2015): 2202-3.
"Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies." J Natl Cancer Inst 109, no. 8 (2017).
"Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Future Oncol 12, no. 11 (2016): 1359-67.
"Quantifying center of pressure variability in chondrodystrophoid dogs." Vet J 226 (2017): 26-31.
"P-Value Precision and Reproducibility." Am Stat 65, no. 4 (2011): 213-221.
"Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer." Clin Cancer Res 26, no. 1 (2020): 82-92.
"PreMeta: a tool to facilitate meta-analysis of rare-variant associations." BMC Genomics 18, no. 1 (2017): 160.
"Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
"Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
"Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
"Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
"Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
"Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
"Precision Medicine Approach to Develop and Internally Validate Optimal Exercise and Weight-Loss Treatments for Overweight and Obese Adults With Knee Osteoarthritis: Data From a Single-Center Randomized Trial." Arthritis Care Res (Hoboken) 73, no. 5 (2021): 693-701.
"Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies." J Clin Oncol 35, no. 25 (2017): 2885-2892.
"Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies." J Clin Oncol 35, no. 25 (2017): 2885-2892.
"PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation." Sci Transl Med 8, no. 369 (2016): 369ra175.
"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
"A penalized likelihood approach for investigating gene-drug interactions in pharmacogenetic studies." Biometrics 71, no. 2 (2015): 529-37.
"Parameter estimation in Cox models with missing failure indicators and the OPPERA study." Stat Med 34, no. 30 (2015): 3984-96.
"Parameter estimation in Cox models with missing failure indicators and the OPPERA study." Stat Med 34, no. 30 (2015): 3984-96.
"Optimal treatment regimes for survival endpoints using a locally-efficient doubly-robust estimator from a classification perspective." Lifetime Data Anal 23, no. 4 (2017): 585-604.
"A nonparametric spatial model for periodontal data with non-random missingness." J Am Stat Assoc 108, no. 503 (2013).
"A nonparametric spatial model for periodontal data with non-random missingness." J Am Stat Assoc 108, no. 503 (2013).
"Noncrossing quantile regression curve estimation." Biometrika 97, no. 4 (2010): 825-838.
"Nomenclature for alleles of the thiopurine methyltransferase gene." Pharmacogenet Genomics 23, no. 4 (2013): 242-8.
"Multivariate longitudinal shape analysis of human lateral ventricles during the first twenty-four months of life." PLoS One 9, no. 9 (2014): e108306.
"Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
"Multisensory Logic of Infant-Directed Aggression by Males." Cell 175, no. 7 (2018): 1827-1841.e17.
"Modeling survival distribution as a function of time to treatment discontinuation: A dynamic treatment regime approach." Biometrics 74, no. 3 (2018): 900-909.
"On model selections for repeated measurement data in clinical studies." Stat Med 34, no. 10 (2015): 1621-33.
"Meta-analysis of gene-level associations for rare variants based on single-variant statistics." Am J Hum Genet 93, no. 2 (2013): 236-48.
"Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group." Stat Med 34, no. 14 (2015): 2181-95.
"Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group." Stat Med 34, no. 14 (2015): 2181-95.
"JMFit: A SAS Macro for Joint Models of Longitudinal and Survival Data." J Stat Softw 71, no. 3 (2016).
"Interquantile Shrinkage in Regression Models." J Comput Graph Stat 22, no. 4 (2013).
"Interquantile Shrinkage and Variable Selection in Quantile Regression." Comput Stat Data Anal 69 (2014): 208-219.
"Incorporating Patient Preferences into Estimation of Optimal Individualized Treatment Rules." Biometrics 74, no. 1 (2018): 18-26.
"Incorporating covariates in skewed functional data models." Biostatistics 16, no. 3 (2015): 413-26.
"Improved detection of epigenomic marks with mixed-effects hidden Markov models." Biometrics 75, no. 4 (2019): 1401-1413.
"Impact of Esophageal Motion on Dosimetry and Toxicity With Thoracic Radiation Therapy." Technol Cancer Res Treat 18 (2019): 1533033819849073.
"On the impact of covariate measurement error on spatial regression modelling." Environmetrics 25, no. 8 (2014): 560-570.
"Identifying individual risk rare variants using protein structure guided local tests (POINT)." PLoS Comput Biol 15, no. 2 (2019): e1006722.
"A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101." Clin Cancer Res 18, no. 18 (2012): 5099-109.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Generation of a Transcriptional Radiation Exposure Signature in Human Blood Using Long-Read Nanopore Sequencing." Radiat Res 193, no. 2 (2020): 143-154.
"FSR Methods for Second-Order Regression Models." Comput Stat Data Anal 55, no. 6 (2011): 2026-2037.
"A framework for transcriptome-wide association studies in breast cancer in diverse study populations." Genome Biol 21, no. 1 (2020): 42.
"Factor selection and structural identification in the interaction ANOVA model." Biometrics 69, no. 1 (2013): 70-9.
"Evaluating haplotype effects in case-control studies via penalized-likelihood approaches: prospective or retrospective analysis?" Genet Epidemiol 34, no. 8 (2010): 892-911.
"